Kles KA - Search Results

1

Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin.

McGill JB, King GL, Berg PH, Price KL, Kles KA, Bastyr EJ, Hyslop DL. McGill JB, et al. Among authors: kles ka. Expert Opin Drug Saf. 2006 Nov;5(6):835-45. doi: 10.1517/14740338.5.6.835. Expert Opin Drug Saf. 2006. PMID: 17044810 Review.

2

Factors that impact symptomatic diabetic peripheral neuropathy in placebo-administered patients from two 1-year clinical trials.

Tesfaye S, Tandan R, Bastyr EJ 3rd, Kles KA, Skljarevski V, Price KL; Ruboxistaurin Study Group. Tesfaye S, et al. Among authors: kles ka. Diabetes Care. 2007 Oct;30(10):2626-32. doi: 10.2337/dc07-0608. Epub 2007 Jul 10. Diabetes Care. 2007. PMID: 17623822

3

How the diabetic eye loses vision.

Davidson JA, Ciulla TA, McGill JB, Kles KA, Anderson PW. Davidson JA, et al. Among authors: kles ka. Endocrine. 2007 Aug;32(1):107-16. doi: 10.1007/s12020-007-0040-9. Epub 2007 Sep 27. Endocrine. 2007. PMID: 17992608 Review.

4

Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy.

PKC-DRS2 Group; Aiello LP, Davis MD, Girach A, Kles KA, Milton RC, Sheetz MJ, Vignati L, Zhi XE. PKC-DRS2 Group, et al. Among authors: kles ka. Ophthalmology. 2006 Dec;113(12):2221-30. doi: 10.1016/j.ophtha.2006.07.032. Epub 2006 Sep 20. Ophthalmology. 2006. PMID: 16989901 Clinical Trial.

5

Effect of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2).

Sheetz MJ, Aiello LP, Shahri N, Davis MD, Kles KA, Danis RP; Mbdv Study Group. Sheetz MJ, et al. Among authors: kles ka. Retina. 2011 Jun;31(6):1053-9. doi: 10.1097/IAE.0b013e3181fe545f. Retina. 2011. PMID: 21386766 Clinical Trial.

6

Diagnostic tools for diabetic sensorimotor polyneuropathy.

Kles KA, Bril V. Kles KA, et al. Curr Diabetes Rev. 2006 Aug;2(3):353-61. doi: 10.2174/157339906777950598. Curr Diabetes Rev. 2006. PMID: 18220640 Review.

7

Role of protein kinase C inhibition in the development of diabetic microvascular complications.

Skljarevski V, Ferdinand SJ, Kles KA. Skljarevski V, et al. Among authors: kles ka. Expert Rev Endocrinol Metab. 2007 May;2(3):321-329. doi: 10.1586/17446651.2.3.321. Expert Rev Endocrinol Metab. 2007. PMID: 30743811

8

Pathophysiology and treatment of diabetic peripheral neuropathy: the case for diabetic neurovascular function as an essential component.

Kles KA, Vinik AI. Kles KA, et al. Curr Diabetes Rev. 2006 May;2(2):131-45. doi: 10.2174/157339906776818569. Curr Diabetes Rev. 2006. PMID: 18220622 Review.

9

Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease.

Small DS, Wrishko RE, Ernest CS 2nd, Ni L, Winters KJ, Farid NA, Li YG, Brandt JT, Salazar DE, Borel AG, Kles KA, Payne CD. Small DS, et al. Among authors: kles ka. J Clin Pharm Ther. 2009 Oct;34(5):585-94. doi: 10.1111/j.1365-2710.2009.01068.x. J Clin Pharm Ther. 2009. PMID: 19744014

10

fMLP induces Hsp27 expression, attenuates NF-kappaB activation, and confers intestinal epithelial cell protection.

Carlson RM, Vavricka SR, Eloranta JJ, Musch MW, Arvans DL, Kles KA, Walsh-Reitz MM, Kullak-Ublick GA, Chang EB. Carlson RM, et al. Among authors: kles ka. Am J Physiol Gastrointest Liver Physiol. 2007 Apr;292(4):G1070-8. doi: 10.1152/ajpgi.00417.2006. Epub 2006 Dec 21. Am J Physiol Gastrointest Liver Physiol. 2007. PMID: 17185631 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15 results

Search Page

Filters